Vortioxetine: a New Treatment for Major Depressive Disorder

  title={Vortioxetine: a New Treatment for Major Depressive Disorder},
  author={K Ryan Connolly and Michael E. Thase},
  journal={Expert Opinion on Pharmacotherapy},
  pages={421 - 431}
INTRODUCTION Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD. [] Key Method Pre-approval studies were identified as all randomized, placebo-controlled studies of vortioxetine listed on clinicaltrials.gov.

A “Real-World” Chart Review Study of Monotherapy and Adjunctive Vortioxetine in Clinical Practice

Vortioxetine was found to be efficacious with minimal side effects and may improve cognition in depression and has a lower incidence of treatment-emergent sexual dysfunction.

Vortioxetine: A Review in Cognitive Dysfunction in Depression

Vortioxetine is a useful treatment option in patients with MDD where impaired cognitive function is apparent and significantly improved a subjective measure of cognitive function (the Perceived Deficits Questionnaire) and an objective measure of functional capacity (the University of San Diego performance-based skills assessment).

Vortioxetine and Lewy Body Disorders

The use of Vortioxetine for patients with Lewy Body Disorders may present complications due to its effect on neurotransmitter pathways affected by Lewy pathology, as well as its interactions with medications frequently prescribed to that population, including Bupropion and Carbidopa-Levodopa.

Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018

The efficacy of tranylcypromine, paroxetine, clonazepam, alprazolam and escitalopram is confirmed, and vortioxetine and TMS, with duration of 4 or more weeks, also seems to be effective.

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions

Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses.

Neuroanatomical, Biochemical, and Functional Modifications in Brain Induced by Treatment with Antidepressants.

An overview of structural changes in the brain during depression; different neurobiological theories and novel drug development; strategy of augmentation with combinatorial therapy; receptors and targets of actions of antidepressants; and involvement of key signaling factors in the regulation of depression, pharmacology, metabolism, and the underlying principles involved in displaying how the application of antidepressants modulates the structure and function of the brain are presented.

Paroxetine versus Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study.

This observational study aims to compare paroxetine and vortioxetine in a sample of patients affected by postmenopausal depression attending the Anxiety and Depression Clinic in terms of efficacy in determining clinical remission (HDRS ≤ 7) and tolerability; improvement of autonomic and cognitive symptoms.

Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports

A pattern of co-reported adverse events that is consistent with labelled adverse events for vortioxetine and the safety profile for selective serotonin reuptake inhibitors in general was revealed.

An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder

Some support for the use of vortioxetine in the management of panic disorder is provided, with a statistically significant decrease in the occurrence of panic attacks and a moderate improvement in the quality of life.



Rediscovering Trazodone for the Treatment of Major Depressive Disorder

Overall, trazodone is an effective and well tolerated antidepressant (SARI) with an important role in the current treatment of MDD both as monotherapy and as part of a combination strategy.

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

Vilazodone has demonstrated efficacy in 2 large, randomized, double-blind, placebo-controlled trials in major depressive disorder and is effective in patients with high levels of anxiety, and future studies corroborate the clinical benefits attributed to its mechanism of action.

Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.

The results suggest that vortioxetine may be an effective treatment option for MDD, but they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs.

Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

A large and significant treatment effect on the Montgomery-Asberg Depression Rating Scale and statistically significant improvement on the CGI-S demonstrated meaningful depressive symptom improvements.

The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.

The issues that were important to the FDA's approval decision are emphasized, particularly the difference in the effective dose in domestic and foreign studies, and several new labeling features are noted, specifically, description of time course of treatment response and detailed sexual dysfunction evaluation.

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action

The preclinical and clinical data suggest that trazodone acts as an antidepressant via antagonist action at 5-HT2/1C receptors, while fluoxetine likely acts as a antidepressant via inhibition of 5- HT uptake.

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder

Vortioxetine demonstrated a favourable safety and tolerability profile and maintained effectiveness over 12 months of treatment, as with all open-label studies, the conclusions that can be drawn are limited by the lack of a placebo control.

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.

Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Vilazodone is effective for the treatment of MDD in adults, with symptom relief starting at 1 week, and is well tolerated at a dose of 40 mg/day, according to the intention-to-treat sample.

Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

The trazodone Contramid formulation was more effective than placebo in major depressive disorder and was well tolerated, including improvements in quality of sleep.